HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05102214 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Solid Tumors
Non-small Cell Lung Cancer

Interventions

DRUG: HLX301

Sponsor

Shanghai Henlius Biotech